Human Epilepsy Project 2: Resistant Focal Seizures Study

CompletedOBSERVATIONAL
Enrollment

157

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

July 30, 2022

Study Completion Date

September 30, 2022

Conditions
EpilepsyBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesBiomarkers
Trial Locations (10)

10016

New York University, New York

10075

Northwell Health Comprehensive Epilepsy Center, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

33136

University of Miami, Miami

37232

Vanderbilt Epilepsy Center, Nashville

55102

Minnesota Epilepsy Group, Saint Paul

55905

Mayo Clinic, Rochester

83702

Idaho Comprehensive Epilepsy Center, Boise

94143

University of California San Francisco, San Francisco

06520

Yale Comprehensive Epilepsy Center, New Haven

All Listed Sponsors
collaborator

The Epilepsy Study Consortium

OTHER

collaborator

UCB Biopharma S.P.R.L.

INDUSTRY

lead

Epilepsy Foundation of America

OTHER

NCT03531008 - Human Epilepsy Project 2: Resistant Focal Seizures Study | Biotech Hunter | Biotech Hunter